Drug Profile
GS 3435
Latest Information Update: 22 May 2001
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 22 May 2001 Profile reviewed but no significant changes made
- 31 Aug 1998 No-Development-Reported for Influenza virus infections in USA (Unknown route)
- 15 May 1995 New profile